A cell-based assay for the detection of neutralizing antibodies against alemtuzumab
Aim: The humanized anti-CD52 monoclonal antibody alemtuzumab depletes lymphocytes and is currently used to treat relapsing multiple sclerosis. During treatment, anti-alemtuzumab antibodies may develop and reduce effective lymphocyte depletion in future treatment cycles. Results: Alemtuzumab–Alexa Fl...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Taylor & Francis Group
2020-04-01
|
| Schriftenreihe: | BioTechniques |
| Schlagworte: | |
| Online-Zugang: | https://www.future-science.com/doi/10.2144/btn-2019-0122 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|